{"name":"Korro Bio","slug":"korro","ticker":"KRRO","exchange":"NASDAQ","domain":"korrobio.com","description":"Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"49","ceo":"Ram Aiyar","sector":"RNA Editing Therapeutics","stockPrice":11.16,"stockChange":-0.04,"stockChangePercent":-0.36,"marketCap":"$161M","metrics":{"revenue":6392000,"revenueGrowth":181.5,"grossMargin":0,"rdSpend":65575000,"netIncome":-117260000,"cash":113970000,"dividendYield":0,"peRatio":-2.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"KB-001 patent cliff ($0.0B at risk)","drug":"KB-001","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"KB-002 patent cliff ($0.0B at risk)","drug":"KB-002","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"KRRO Receives FDA Orphan Drug Designation for KB-001","summary":"Korro Bio announced that the FDA has granted Orphan Drug Designation to KB-001, a treatment for a rare genetic disorder.","drugName":"KB-001","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"KRRO Reports Third Quarter 2023 Financial Results","summary":"Korro Bio reported its third-quarter 2023 financial results, with a net loss of $23.4 million and a cash balance of $143.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"KRRO Enters into Collaboration Agreement with Leading Research Institution","summary":"Korro Bio announced a collaboration agreement with a leading research institution to advance the development of its RNA editing therapeutics.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFA4VnBNODNzNTFRcTN6ZzRPQzN4Y25aWl9zTFk2WEFPLTVMX2RDUno5VzdZRjdSWlhoUW8xRDlranR3elJwQU9wWjh3a0dsdw?oc=5","date":"2026-03-31","type":"pipeline","source":"MEXC Exchange","summary":"KRRO Price Today: Korro Bio, Inc. Stock Price, Quote & Chart - MEXC Exchange","headline":"KRRO Price Today: Korro Bio, Inc. Stock Price, Quote & Chart","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-14","type":"trial","source":"simplywall.st","summary":"Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation - simplywall.st","headline":"Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOLUo3bmxrRk9uU29CeHN4VExjaVdJT2hBZl9KellDTHhKekJVUENiT2FqMVVJSC00SWUzZURWOGRMZzY2eGZPREhmZmw4dEpRYTF5aGNtanh2eXZSSWwzWjlpTXcwRVh5QmFxNDVJOFUzTHNadF93YlJmbTE3ZllzVHlWcW5CLUJiYWhHRGFfTlRra0hvVDdoNllKQQ?oc=5","date":"2025-11-13","type":"pipeline","source":"BioPharma Dive","summary":"Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing - BioPharma Dive","headline":"Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE56R040MWdDTXM4aDlKNzVjeklZbEV0T1FWUzBPTXdveHRqWHJBZVpWUjdPbU4wS0VibG9JR2dlZFR0WmVmR1d2bVN5VXFtRkxlM284?oc=5","date":"2025-11-13","type":"pipeline","source":"firstwordpharma.com","summary":"More cuts at Korro as lead drug disappoints, Novo pauses collab - firstwordpharma.com","headline":"More cuts at Korro as lead drug disappoints, Novo pauses collab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1CLTJSeHNlcE5kOVNSaDhFVzVZQUd4OXN4MUQyemFHVkJJaTNkTDBNMmxsVS1JSXJQdDRRVjJwLW9lTk1MYzRCZmo2Nk96NDNxWEhyNFgxcEtmUkstLTVqcThPNWNlMVJrckZKdlo5NA?oc=5","date":"2025-11-13","type":"trial","source":"medwatch.com","summary":"Failed study prompts US biotech to halt Novo Nordisk collaboration - medwatch.com","headline":"Failed study prompts US biotech to halt Novo Nordisk collaboration","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOclU4M2NHQUlFMmJyYTBlb3M1NDFJR2pyYzFMSURPV1gtZ0ZRRWVsQThhOGVDay1ZT29sbWwxNkR3Z3dqUEtqa3hnUW4zVEljMmZ5V2dnZmJxQjZEOVpZb1NsZW5RWmhQeWVPY2dBVXhkbkFURnRKb3ZpVk03RnBUcG44RDBVbml2bDhFeFZzNnRQdy1LbDdsT2RxQmxiN2s2NkV3c092dGtiR0JQ?oc=5","date":"2025-11-13","type":"pipeline","source":"Fierce Biotech","summary":"Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact - Fierce Biotech","headline":"Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-23","type":"pipeline","source":"simplywall.st","summary":"Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely? - simplywall.st","headline":"Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN29mYkNfUHJ0SEVTaTRfaXRKTmxnRnZKR3hKZndLaEFfbWNhZTdUQlVRb1VlOFd3UXdmU0VuS1ZsbE0xSVZlRWlvYXNJcVJrbTNJenNHNWMyVG51eEkxNHdsZ0Z4dEhHM3RwdXEzM1NVVXBnX2ZILUt6akdqMm15WUpVTkNJUnR6bFp5SDU0VnlBZlpTdFFiLVBlWXJKLXdpVi1uOTYyZC1sZw?oc=5","date":"2025-05-08","type":"trial","source":"Fierce Biotech","summary":"Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership - Fierce Biotech","headline":"Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPMHNPNUVsWG53QlBmbW9yVWkzZUctNWVJVUQzNkZHR0NTaUxseWgwTHZpejRLWjl1RnRyX054LW9ua0E1N05VMmhJUWFlSklTWmNLdW5ZSDIxUzY4a2k2dkdHQk9DTmJ5WW1qZVVCbExrMHZRNjhJVlRaMi1PSXdnUkRUZnJJNzlHX2ZURW0xNnE5VVNoMWN0ZmpvZU13ZUxC?oc=5","date":"2025-04-01","type":"pipeline","source":"citybiz","summary":"Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer - citybiz","headline":"Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOcUxueG5tN2NRMHdRbEhhOTFMRjQ1LXFvdmhueFFNaTZQRW1XVG5JNjJpRm8yU3hrNjJQVWcxSW5IMWJoWl83Y19OOXRESGdGSGNhSUNLZE9ES1pLS21mcGoteHQ1dnFwQ1VBcHhLTnU5VGpydmk0dVppSFlxNEtzUGFwb0p0RV9JRm9WMnRKTQ?oc=5","date":"2024-09-17","type":"deal","source":"The Pharma Letter","summary":"Korro Bio inks cardiometabolics deal with Novo Nordisk - The Pharma Letter","headline":"Korro Bio inks cardiometabolics deal with Novo Nordisk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE0tQ1RlYkdHbWt6dXYxRVBLb1RPaDBORFB6QlY1MzdtWUpieDBCUmR5c1hsZFhudk50MGJoa0JNX0NqNGF5TVkzb0FobHlESWNMT2JhTVVkZzhMWldY?oc=5","date":"2024-07-20","type":"pipeline","source":"TradingView","summary":"KRRO Stock Price and Chart — NASDAQ:KRRO - TradingView","headline":"KRRO Stock Price and Chart — NASDAQ:KRRO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9pdHJhYXZEUGdlMHJITlA1VXk0NGxfZ3hwbDByZHV1WHBpS2FOd1lDQmZMYUdfeTc3NGdXcXlfcnNpRnRhUjRIVTNsZEZOTDdU?oc=5","date":"2023-11-10","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"KB-001","drugSlug":"kb-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"KB-002","drugSlug":"kb-002","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Rare Genetic Disorders","Neurological Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":6392000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":6392000,"period":"2025-12-31"},{"value":2271000,"period":"2024-12-31"},{"value":2271000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":65575000,"rdSpendHistory":[{"period":"2025-12-31","value":65575000},{"period":"2024-12-31","value":63636000},{"period":"2023-12-31","value":57250000},{"period":"2022-12-31","value":42201000}],"sgaSpend":28159000,"operatingIncome":-87342000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-87342000},{"period":"2024-12-31","value":-91910000},{"period":"2023-12-31","value":-84534000},{"period":"2022-12-31","value":-58998000}],"netIncome":-117260000,"netIncomeHistory":[{"period":"2025-12-31","value":-117260000},{"period":"2024-12-31","value":-83581000},{"period":"2023-12-31","value":-81172000},{"period":"2022-12-31","value":-58032000}],"eps":-9.37,"epsHistory":[{"period":"2024-12-31","value":-9.37},{"period":"2023-12-31","value":-53.08},{"period":"2022-12-31","value":-7.252837},{"period":"2021-12-31","value":-2.744435}],"cash":21824000,"cashHistory":[{"period":"2025-12-31","value":21824000},{"period":"2024-12-31","value":55643000},{"period":"2023-12-31","value":166150000},{"period":"2022-12-31","value":36333000}],"totalAssets":113506000,"totalLiabilities":62067000,"totalDebt":43486000,"equity":51439000,"operatingCashflow":-78561000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-78561000},{"period":"2024-12-31","value":-60074000},{"period":"2023-12-31","value":-67283000},{"period":"2022-12-31","value":-53645000}],"capex":-518000,"capexHistory":[{"period":"2025-12-31","value":-518000},{"period":"2024-12-31","value":-17902000},{"period":"2023-12-31","value":-7836000},{"period":"2022-12-31","value":-5212000}],"freeCashflow":-79079000,"dividendsPaid":null,"buybacks":null,"employees":49,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":6190000,"ebit":-15883000,"ebitda":-15234000,"period":"2025-12-31","revenue":1292000,"epsBasic":null,"netIncome":-50042000,"rdExpense":10985000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-15883000},{"sga":6507000,"ebit":-19237000,"ebitda":-18058000,"period":"2025-09-30","revenue":1090000,"epsBasic":-1.92,"netIncome":-18061000,"rdExpense":13820000,"epsDiluted":-1.92,"grossProfit":null,"operatingIncome":-19237000},{"sga":7631000,"ebit":-27202000,"ebitda":-25975000,"period":"2025-06-30","revenue":1460000,"epsBasic":-2.74,"netIncome":-25770000,"rdExpense":21031000,"epsDiluted":-2.74,"grossProfit":null,"operatingIncome":-27202000},{"sga":7831000,"ebit":-25020000,"ebitda":-23795000,"period":"2025-03-31","revenue":2550000,"epsBasic":-2.49,"netIncome":-23387000,"rdExpense":19739000,"epsDiluted":-2.49,"grossProfit":null,"operatingIncome":-25020000},{"sga":8349000,"ebit":-23040000,"ebitda":-21787000,"period":"2024-12-31","revenue":2271000,"epsBasic":null,"netIncome":-21199000,"rdExpense":16962000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-23040000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-2.26,"netIncome":null,"rdExpense":null,"epsDiluted":-2.26,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.16,"previousClose":11.2,"fiftyTwoWeekHigh":55.89,"fiftyTwoWeekLow":5.2,"fiftyTwoWeekRange":"5.204 - 55.89","fiftyDayAverage":12.42,"twoHundredDayAverage":18.59,"beta":2.23,"enterpriseValue":90447792,"forwardPE":-2.3,"priceToBook":1.35,"priceToSales":41.89,"enterpriseToRevenue":23.54,"enterpriseToEbitda":-1.14,"pegRatio":0,"ebitda":-79323000,"ebitdaMargin":0,"freeCashflow":-39038124,"operatingCashflow":-70183000,"totalDebt":42885000,"debtToEquity":35.8,"currentRatio":8.13,"returnOnAssets":-26.8,"returnOnEquity":-87.8,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":20.38,"targetHighPrice":30,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.6,"institutionHeldPercent":78.1,"sharesOutstanding":14422571,"floatShares":9581202,"sharesShort":1117429,"shortRatio":7.3,"shortPercentOfFloat":7.8,"epsTrailing":-11.68,"epsForward":-4.86,"revenuePerShare":0.39,"bookValue":8.29,"officers":[{"age":47,"name":"Dr. Ram  Aiyar MBA, Ph.D.","title":"CEO, President, Interim CFO, Principal Financial Officer & Director"},{"age":null,"name":"Dr. Loic  Vincent Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Dr. Jeffrey M. Cerio J.D., Pharm.D.","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Dr. Andrew  Fraley Ph.D.","title":"Co-Founder & Advisor"},{"age":null,"name":"Dr. Joshua  Rosenthal Ph.D.","title":"Co-Founder & Advisor"},{"age":52,"name":"Mr. Todd  Chappell M.B.A.","title":"Chief Operating Officer"},{"age":42,"name":"Mr. Oliver  Dolan","title":"Senior VP of Finance & Principal Accounting Officer"},{"age":null,"name":"Ms. Stephanie  Engels","title":"Chief People Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.korrobio.com","phone":"617 468 1999"}}